Eli Lilly and Company today announced the U.S. Food and Drug Administration (FDA) approved a label expansion for Zepbound® (tirzepatide) to include the four-dose single-patient use KwikPen® that ...
The FDA has approved a label expansion for tirzepatide (Zepbound; Eli Lilly), allowing use of a 4-dose, single-patient-use KwikPen that delivers a full month of treatment in 1 device for chronic ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results